Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

In vitro effect of hydroxychloroquine on pluripotent stem cells and their cardiomyocytes derivatives

Kamga Kapchoup et al., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1128382
Jul 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
In vitro study of HCQ with mouse and human pluripotent stem cells and their cardiomyocyte derivatives. Results suggest HCQ has differential dose-dependent effects in mouse vs. human stem cell-derived cardiomyocytes. At lower concentrations (20-50μM), HCQ promoted proliferation and contractility. However at higher doses, HCQ was toxic. 20μM of HCQ promoted proliferation of stem cells, suggesting it may have a cardioprotective effect and could be a candidate for tissue repair. But higher doses above 100μM induced apoptosis and negative inotropic effects. The authors recommend careful HCQ dosing to avoid potential cardiotoxicity. Monitoring of treatment in lifelong users is also advised due to HCQ's long half-life.
Kamga Kapchoup et al., 12 Jul 2023, China, peer-reviewed, 3 authors. Contact:
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperHCQAll
In vitro effect of hydroxychloroquine on pluripotent stem cells and their cardiomyocytes derivatives
Michelle Vanessa Kamga Kapchoup, Jürgen Hescheler, Filomain Nguemo
Frontiers in Pharmacology, doi:10.3389/fphar.2023.1128382
Introduction: Hydroxychloroquine (HDQ) is an antimalarial drug that has also shown its effectiveness in autoimmune diseases. Despite having side effects such as retinopathy, neuromyopathy and controversial cardiac toxicity, HDQ has been presented and now intensively studied for the treatment and prevention of coronavirus disease 2019 . Recent works revealed both beneficial and toxic effects during HDQ treatment. The cardiotoxic profile of HDQ remains unclear and identifying risk factors is challenging. Methods: Here, we used well-established cell-cultured to study the cytotoxic effect of HDQ, mouse induced pluripotent stem cells (miPSC) and their cardiomyocytes (CMs) derivatives were exposed to different concentrations of HDQ. Cell colony morphology was assessed by microscopy whereas cell viability was measured by flow cytometry and impedance-based methods. The effect of HDQ on beating activity of mouse and human induced pluripotent stem cellderived CMs (miPSC-CMs and hiPSC-CMs, respectively) and mouse embryonic stem cell-derived CMs (mESC-CMs) were captured by the xCELLigence RTCA and microelectrode array (MEA) systems. Results and discussion: Our results revealed that 20 µM of HDQ promotes proliferation of stem cells used suggesting that if appropriately monitored, HDQ may have a cardioprotective effect and may also represent a possible candidate for tissue repair. In addition, the field potential signals revealed that higher doses of this medication caused bradycardia that could be reversed with a higher concentration of ß-adrenergic agonist, Isoproterenol (Iso). On the contrary, HDQ caused an increase in the beating rate of hiPSC-CMs, which was further helped upon application of Isoproterenol (Iso) suggesting that HDQ and Iso may also work synergistically. These results indicate that HDQ is potentially toxic at high concentrations and can modulate the beating activity of cardiomyocytes. Moreover, HDQ could have a synergistic inotropic effect with isoproterenol on cardiac cells.
Author contributions FN and MK conceived, planed and designed the experiments; MK performed the measurements and analysis. MK drafted and wrote the manuscript with input from all authors. JH and FN revised the manuscript critically. All authors contributed to the article and approved the submitted version. Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Al-Rawi, Meggitt, Williams, Wahie, Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus, Lupus, doi:10.1177/0961203317727601
Both, Van De Peppel, Zillikens, Koedam, Van Leeuwen et al., Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro, J. Cell. Mol. Med, doi:10.1111/jcmm.13373
Both, Zillikens, Hoorn, Zietse, Van Laar et al., Hydroxychloroquine is cardioprotective in neonatal RAT cardiomyocytes exposed to simulated myocardial ischaemic/reperfusion injury: An effect mediated through ERK phosphorylation, Calcif. tissue Int, doi:10.1093/rheumatology/keu093.003
Browning, Pharmacology of chloroquine and hydroxychloroquine
Chloroquine Retin ; Chen, Wang, Lin, Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia, Clin. Toxicol, doi:10.1080/15563650500514558
Costedoat-Chalumeau, Amoura, Hulot, Hammoud, Aymard et al., Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus, Arthritis Rheum, doi:10.1002/art.22156
Dubois, Antimalarials in the management of discoid and systemic lupus erythematosus, Semin. Arthritis Rheum, doi:10.1016/0049-0172(78)90033-1
Fatima, Xu, Nguemo, Kuzmenkin, Burkert et al., Murine transgenic iPS cell line for monitoring and selection of cardiomyocytes, Stem Cell Res, doi:10.1016/j.scr.2016.07.007
Folkerts, Hilgendorf, Wierenga, Jaques, Mulder et al., Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia, Cell Death Dis, doi:10.1038/cddis.2017.317
Fong, Trinkaus, Adkins, Vij, Devine et al., None
Furst, Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases, Lupus, doi:10.1177/0961203396005001041
Garcia-Cremades, Solans, Hughes, Ernest, Wallender et al., Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing, Clin. Pharmacol. Ther, doi:10.1002/cpt.1856
Hamad, Derichsweiler, Papadopoulos, Nguemo, Saric et al., Generation of human induced pluripotent stem cell-derived cardiomyocytes in 2D monolayer and scalable 3D suspension bioreactor cultures with reduced batch-to-batch variations, Theranostics, doi:10.7150/thno.32058
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0
Jackson, Hansen, Gustafson, Abstract 2084: Pharmacokinetic and pharmacodynamic assessment of autophagy inhibition following hydroxychloroquine in mice, Cancer Res, doi:10.1158/1538-7445.am2016-2084
Jordaan, Dumotier, Traebert, Miller, Ghetti et al., Cardiotoxic potential of hydroxychloroquine, chloroquine and azithromycin in adult human primary cardiomyocytes, Toxicol. Sci. official J. Soc. Toxicol, doi:10.1093/toxsci/kfaa194
Joyce, Fabre, Mahon, Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: Key diagnostic features and literature review, Eur. heart J. Acute Cardiovasc. care, doi:10.1177/2048872612471215
Lakshminarayanan, Walsh, Mohanraj, Factors associated with low bone mineral density in female patients with systemic lupus erythematosus, J. rheumatology
Li, Cao, Li, Li, Yu et al., Hydroxychloroquine induced lung cancer suppression by enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like macrophages, J. Exp. Clin. Cancer Res, doi:10.1186/s13046-018-0938-5
Liu, Bi, Chen, Guo, Tu et al., Time-dependent distribution of hydroxychloroquine in cynomolgus macaques using population pharmacokinetic modeling method, Front. Pharmacol, doi:10.3389/fphar.2020.602880
Liu, Cao, Xu, Wang, Zhang et al., None
Mackenzie, Scherbel, Chloroquine and hydroxychloroquine in rheumatological therapy, Clin. Rheumatic Dis, doi:10.1016/s0307-742x(21)00317-9
Merino, Martínez-Cossiani, Iniesta, Escobar, Rey et al., COVID-19 and QT interval prolongation: More than just drug toxicity?, doi:10.1093/europace/euaa145
Mok, Mak, Ma, Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus, Lupus, doi:10.1191/0961203305lu2039oa
Mubagwa, Cardiac effects and toxicity of chloroquine: A short update
Oscanoa, Romero-Ortuno, Carvajal, Savarino, A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?, Int. J. Antimicrob. agents, doi:10.1016/j.ijantimicag.2020.106078
Pfannkuche, Liang, Hannes, Xi, Fatima et al., Cardiac myocytes derived from murine reprogrammed fibroblasts: Intact hormonal regulation, cardiac ion channel expression and development of contractility, Cell. Physiology Biochem, doi:10.1159/000227815
Phillips, Chun, Hydroxychloroquine retinopathy after short-term therapy, Retin Cases Brief. Rep, doi:10.1097/ICB.0000000000000006
Stokkermans, Goyal, Bansal, Trichonas, Chloroquine and hydroxychloroquine toxicity
Sutanto, Heijman, Beta-adrenergic receptor stimulation modulates the cellular proarrhythmic effects of chloroquine and azithromycin, Front. Physiol, doi:10.3389/fphys.2020.587709
Tripathy, Dassarma, Roy, Chabalala, Matsabisa, A review on possible modes of action of chloroquine/hydroxychloroquine: Repurposing against SAR-CoV-2 (COVID-19) pandemic, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.106028
Wernig, Meissner, Foreman, Brambrink, Ku et al., In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state, Nature, doi:10.1038/nature05944
Wolfe, Marmor, Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus, Arthritis Care Res. Hob, doi:10.1002/acr.20133
Wong, Gurung, Wong, Mak, Tse et al., Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues, J. Mol. Cell Cardiol, doi:10.1016/j.yjmcc.2020.12.014
Yang, Ray, Krafts, Cell proliferation
Yang, Wu, Liu, Liu, Guo et al., Cytotoxicity evaluation of chloroquine and hydroxychloroquine in multiple cell lines and tissues by dynamic imaging system and PBPK model, Front. Pharmacol, doi:10.3389/fphar.2020.574720
Yusuf, Sharma, Luqmani, Downes, Hydroxychloroquine retinopathy, doi:10.1038/eye.2016.298
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop